BioSpace News Archive

Marrone Bio Innovations, Inc. (NASDAQ: MBII) (MBI), an international leader in sustainable bioprotection and plant health solutions, announced today that REGALIA ® MAXX biofungicide received the first approval for indoor and outdoor use on cannabis and hemp in Canada. Cannabis and hemp have been relatively small crops in Canada until lifestyle cannabis was approved in 2018. According to Health Canada, 77,800 acres of hemp were grown in 2018,

Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced the voting results from its 2020 Annual General Meeting of Shareholders held at its corporate headquarters in Laval, Québec.

Surmodics Names Gordon Weber as Senior Vice President of Legal, General Counsel and Secretary

LabLynx, Inc. announces the latest edition of industry guide now available at LIMSforum.com.

Data include retrospective analysis of landmark STOP 2 Study highlighting correlation between higher hemoglobin levels and lower transcranial Doppler (TCD) flow velocities in children with sickle cell disease SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that four abstracts will be presented during the virtual edition of the 25 th Annual European Hematology Association (EHA) Congress taking place June 11-1

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new clinical data on CG-806, its oral, first-in-class FLT3/BTK cluster selective kinase inhibitor, will be presented in a poster presentation at the 25 th Congress of the European Hematology Association, EHA25 Virtual Congr

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , an immunology company developing treatments that harness the patient’s innate immune system to fight disease today reported its financial results for the first quarter ended March 31, 2020 and is providing a business update. INmune Bio will hold a conference call today at 4:30 PM Eastern Time. To participate in the call, please dial 201-389-0923 five minutes before the schedule time. T

- Systematic NGS Program, featuring a Molecular Profiling Test Optimized for Small Tumor Tissue, Supports Widespread Implementation of NGS Testing -

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced that results from the Phase 3 PEGASUS study were selected for oral presentation at the 25th Annual Congress of the European Hematology Association

According to a new market report published by Persistence Market Research “Global Market Study on Cranio Maxillofacial Implants: Asia to Witness Highest Growth by 2020” the global cranio maxillofacial implants market was valued at USD 1,044.7 million in 2014 and is expected to grow at a CAGR of 6.2% from 2014 to 2020, to reach an estimated value of USD 1,498.6 million in 2020.